GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » 3-Year EPS without NRI Growth Rate

Collegium Pharmaceutical (Collegium Pharmaceutical) 3-Year EPS without NRI Growth Rate : 93.10% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical 3-Year EPS without NRI Growth Rate?

Collegium Pharmaceutical's EPS without NRI for the three months ended in Mar. 2024 was $1.45.

During the past 12 months, Collegium Pharmaceutical's average EPS without NRI Growth Rate was 22.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 93.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Collegium Pharmaceutical was 93.10% per year. The lowest was -21.60% per year. And the median was 7.20% per year.


Competitive Comparison of Collegium Pharmaceutical's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's 3-Year EPS without NRI Growth Rate falls into.



Collegium Pharmaceutical 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Collegium Pharmaceutical  (NAS:COLL) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Collegium Pharmaceutical 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
Executives
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021

Collegium Pharmaceutical (Collegium Pharmaceutical) Headlines

From GuruFocus

Collegium Provides 2023 Financial Guidance

By Stock market mentor Stock market mentor 01-04-2023

Collegium to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-06-2022

Insider Alert: An Insider Just Sold Collegium Pharmaceutical Inc Shares

By GuruFocus Research GuruFocus Editor 12-28-2022

Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

By Stock market mentor Stock market mentor 02-06-2023

Collegium to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-17-2022

Collegium to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-27-2022

Collegium to Participate in Jefferies Healthcare Conference

By sperokesalga sperokesalga 06-01-2023